ATE486890T1 - Ephb-rezeptorbindende peptide - Google Patents

Ephb-rezeptorbindende peptide

Info

Publication number
ATE486890T1
ATE486890T1 AT06733967T AT06733967T ATE486890T1 AT E486890 T1 ATE486890 T1 AT E486890T1 AT 06733967 T AT06733967 T AT 06733967T AT 06733967 T AT06733967 T AT 06733967T AT E486890 T1 ATE486890 T1 AT E486890T1
Authority
AT
Austria
Prior art keywords
receptor binding
binding peptides
peptides
ephb receptor
patients
Prior art date
Application number
AT06733967T
Other languages
English (en)
Inventor
Elena Pasquale
Mitchell Koolpe
Original Assignee
Burnham Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Burnham Inst filed Critical Burnham Inst
Application granted granted Critical
Publication of ATE486890T1 publication Critical patent/ATE486890T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/60—Fusion polypeptide containing spectroscopic/fluorescent detection, e.g. green fluorescent protein [GFP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Optics & Photonics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
AT06733967T 2005-01-27 2006-01-26 Ephb-rezeptorbindende peptide ATE486890T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64785205P 2005-01-27 2005-01-27
PCT/US2006/002923 WO2006081418A2 (en) 2005-01-27 2006-01-26 Ephb receptor-binding peptides

Publications (1)

Publication Number Publication Date
ATE486890T1 true ATE486890T1 (de) 2010-11-15

Family

ID=36606084

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06733967T ATE486890T1 (de) 2005-01-27 2006-01-26 Ephb-rezeptorbindende peptide

Country Status (10)

Country Link
US (2) US7582438B2 (de)
EP (1) EP1841790B1 (de)
JP (1) JP2008528614A (de)
KR (1) KR20070118230A (de)
CN (1) CN101146822A (de)
AT (1) ATE486890T1 (de)
AU (1) AU2006208068B2 (de)
CA (1) CA2595892A1 (de)
DE (1) DE602006017964D1 (de)
WO (1) WO2006081418A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006507256A (ja) 2002-09-24 2006-03-02 ザ バーナム インスティチュート Eph受容体活性を調節する新規薬剤
CA2584130A1 (en) * 2004-10-18 2006-04-27 Medimmune, Inc. High cell density process for growth of listeria
WO2006081418A2 (en) 2005-01-27 2006-08-03 The Burnham Institute Ephb receptor-binding peptides
US8343461B2 (en) 2006-03-08 2013-01-01 Wake Forest University Health Sciences Molecular signature of cancer
WO2007103522A2 (en) 2006-03-08 2007-09-13 Wake Forest University Health Sciences Soluble monomeric ephrin a1
JP2009221107A (ja) * 2006-05-24 2009-10-01 Aqumen Biopharmaceuticals Kk エフリンb2の活性を高めるペプチド,その塩,医薬用組成物,治療用キット
WO2008100288A2 (en) * 2006-09-15 2008-08-21 The Burnham Institute High affinity ephb receptor binding compounds and methods of use thereof
US20080112954A1 (en) * 2006-11-10 2008-05-15 Parker College Of Chiropractic Method for treating chronic pain
DK2134374T3 (en) 2007-03-14 2014-02-24 Bionsil S R L In Liquidazione BTK-INHIBITORS FOR USE IN PROCESSING chemotherapeutic agent RESISTANT TUMORS Epithelial
WO2008156642A1 (en) * 2007-06-15 2008-12-24 Vasgene Therapeutics, Inc. Non-immunoglobulin antigen binding scaffolds for inhibiting angiogenesis and tumor growth
CA2748662A1 (en) * 2009-01-19 2010-07-22 Bayer Healthcare Llc Protein conjugate having an endopeptidase-cleavable bioprotective moiety
WO2010108122A1 (en) * 2009-03-20 2010-09-23 Sanford-Burnham Medical Research Institute Targeted delivery of chemotherapeutic agents
US20120207734A1 (en) * 2011-02-14 2012-08-16 Allergan, Inc. Methods of Inhibiting Aberrant Blood Vessel Formation Using Opioid Retargeted Endpeptidases
WO2012112434A1 (en) * 2011-02-14 2012-08-23 Allergan, Inc. Inhibiting aberrant blood vessel formation using retargeted endopeptidases
WO2013106824A1 (en) * 2012-01-13 2013-07-18 Board Of Regents, The University Of Texas System Epherin receptor targeting agents
JP6187960B2 (ja) * 2012-01-20 2017-08-30 日本製粉株式会社 がんの治療又は予防剤
CN105694891B (zh) * 2015-12-30 2018-01-23 深圳先进技术研究院 一种用于荧光寿命编码的量子点及其荧光寿命编码方法
CN105906691B (zh) * 2016-07-05 2019-09-13 珠海诺贝尔国际生物医药研究院有限公司 一种Eph激酶多肽抑制剂及其应用
CN106153920B (zh) * 2016-07-25 2018-04-27 四川大学华西医院 一种肺癌筛查试剂盒
CN114096848A (zh) * 2019-05-08 2022-02-25 得克萨斯州大学系统董事会 治疗性肽

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1333777C (en) 1988-07-01 1995-01-03 Randy M. Berka Aspartic proteinase deficient filamentous fungi
US5824303A (en) 1992-11-13 1998-10-20 Amgen Inc. Eck receptor ligands
PT669929E (pt) 1992-11-13 2007-04-30 Immunex Corp Ligando de elk, uma citoquina
FI952328A7 (fi) 1992-11-13 1995-07-10 Amgen Inc eck-respetorin lignandeja
US5516658A (en) 1993-08-20 1996-05-14 Immunex Corporation DNA encoding cytokines that bind the cell surface receptor hek
US6303769B1 (en) 1994-07-08 2001-10-16 Immunex Corporation Lerk-5 dna
US5864020A (en) 1994-07-20 1999-01-26 Genentech, Inc. HTK ligand
US5795734A (en) 1994-09-19 1998-08-18 President And Fellows Of Harvard College EPH receptor ligands, and uses related thereto
EP0785716B1 (de) 1994-10-05 2006-11-29 Immunex Corporation Als lerk6 bezeichnetes cytokin
US5919905A (en) 1994-10-05 1999-07-06 Immunex Corporation Cytokine designated LERK-6
US5759775A (en) 1994-10-27 1998-06-02 Genetech, Inc. Methods for detecting nucleic acids encoding AL--1 neurotrophic factor
WO1996013518A1 (en) 1994-10-27 1996-05-09 Genentech, Inc. Al-1 neurotrophic factor, a ligand for an eph-related tyrosine kinase receptor
EP0871702B1 (de) 1994-12-06 2005-05-25 Immunex Corporation Cytokin lerk-7
US6057124A (en) 1995-01-27 2000-05-02 Amgen Inc. Nucleic acids encoding ligands for HEK4 receptors
WO1996026958A2 (en) 1995-02-27 1996-09-06 President And Fellows Of Harvard College Eph RECEPTOR LIGAND ELF-2
US6001964A (en) 1995-09-20 1999-12-14 Albert Einstein College Of Medicine Of Yeshiva University Peptides which bind to anti-double stranded DNA antibody
AU2538697A (en) 1996-03-21 1997-10-22 Immunex Corporation Cytokine designated lerk-8
EP0864956A3 (de) * 1997-03-12 1999-03-31 Texas Instruments Incorporated Spannungsregler mit niedrigem Spannungsabfall
US6555321B1 (en) 1997-08-19 2003-04-29 Vanderbilt University Methods for determining cell responses through EphB receptors
EP1060249A1 (de) 1998-03-02 2000-12-20 The Government of the United States represented by the Secretary of the Department of Health and Human Services Epitope peptiden, die immunogenes gegen streptococcus pneumoniae sind
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
AU765940B2 (en) 1998-06-24 2003-10-02 Innogenetics N.V. Particles of HCV envelope proteins: use for vaccination
ES2242437T3 (es) 1998-11-20 2005-11-01 Genentech, Inc. Utilizaciones de agonistas y antagonistas del receptor eph para el tratamiento de trastornos vasculares.
EP1141016A1 (de) 1998-12-18 2001-10-10 Mount Sinai Hospital Dreidimensionale struktur einer domäne vom typ des sterilen alpha motifs
US7060284B1 (en) 1999-08-03 2006-06-13 The Ohio State University Polypeptides and polynucleotides for enhancing immune reactivity to HER-2 protein
WO2002026827A1 (en) * 2000-09-29 2002-04-04 Novartis Ag Extracellular polypeptides of eph b receptors and ephrin b ligands and the corresponding nucleic acid molecules
US20040247592A1 (en) 2001-07-03 2004-12-09 Roifman Chaim M. Ephrin and eph receptor mediated immune modulation
JP2006507256A (ja) * 2002-09-24 2006-03-02 ザ バーナム インスティチュート Eph受容体活性を調節する新規薬剤
EP1605961A4 (de) 2003-03-12 2009-11-11 Vasgene Therapeutics Inc Polypeptid-verbindungen zur hemmung der angiogenese und des tumorwachstums
EP1617864A4 (de) 2003-04-11 2006-06-21 Medimmune Inc Epha2 und nicht-neoplastische hyperproliferative zellstörungen
WO2006081418A2 (en) 2005-01-27 2006-08-03 The Burnham Institute Ephb receptor-binding peptides
WO2008100288A2 (en) 2006-09-15 2008-08-21 The Burnham Institute High affinity ephb receptor binding compounds and methods of use thereof

Also Published As

Publication number Publication date
US20060177452A1 (en) 2006-08-10
CN101146822A (zh) 2008-03-19
AU2006208068B2 (en) 2011-08-04
EP1841790B1 (de) 2010-11-03
CA2595892A1 (en) 2006-08-03
AU2006208068A1 (en) 2006-08-03
WO2006081418A2 (en) 2006-08-03
JP2008528614A (ja) 2008-07-31
US7582438B2 (en) 2009-09-01
US20100183510A1 (en) 2010-07-22
DE602006017964D1 (de) 2010-12-16
HK1108702A1 (en) 2008-05-16
US7999069B2 (en) 2011-08-16
KR20070118230A (ko) 2007-12-14
EP1841790A2 (de) 2007-10-10
WO2006081418A3 (en) 2006-12-07

Similar Documents

Publication Publication Date Title
DE602006017964D1 (de) Ephb-rezeptorbindende peptide
CY1122458T1 (el) Αντισωματα αντι-n3pglu αμυλοειδους βητα πεπτιδιου και χρησεις αυτων
EA201000644A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
ATE502052T1 (de) Monoklonale antikörper gegen den humanen anti- müllerian-hormonrezeptor vom typ ii (amhr-ii)
MY169272A (en) Her2 antibody composition
UA113609C2 (xx) Антигензв'язуючий білок, який зв'язує людський il-23
EA201100923A1 (ru) Антитела человека против тканевого фактора
NO20076021L (no) Antistoffer rettet mot amyloid-betapeptid og metoder som anvender de samme
CY1115935T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
UA107921C2 (xx) Варіанти поліпептидів рецептора іів активіну та їх використання
AR110114A1 (es) ANTICUERPOS CONTRA b-AMILOIDE PIROGLUTAMATO Y SUS USOS
EA201100694A1 (ru) Антитело к cd38 человека и его применение
EA200900040A1 (ru) Молекулы антител, которые связываются с человеческим il-17
CY2017013I1 (el) ΑΝΤΙΣΩΜΑ ΕΝΑΝΤΙΟΝ PDGFR-α ΓΙΑ ΧΡΗΣΗ ΣΤΗΝ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΟΓΚΩΝ
CL2008002886A1 (es) Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende.
UA107490C2 (uk) TNF-α-ЗВ'ЯЗУВАЛЬНИЙ БІЛОК
DK1957539T3 (da) Humane monoklonale antistoffer til proteintyrosinkinase 7 (ptk7) og deres anvendelse
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
EA201071126A1 (ru) Антагонисты рецепторов глюкагона
BR112012011332A2 (pt) agentes direcionados para gadd45beta
NO20082345L (no) Selektive VPAC2 reseptorpeptidagonister
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
ATE404225T1 (de) Radiofluorierte peptide
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
IL189452A0 (en) Therapy with cd4 binding peptides and radiation

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties